Tourette’s syndrome, the most common cause of tics, manifests itself in a wide range of motor and behavioral disorders and is found in men about three times more often than in women. The purpose — to establish the comorbidity of neuropsychiatric disorders in patients with tic hyperkinesis. Material and methods. The study included 111 patients with tic hyperkinesis of various ages and sex, who were outpatiently observed at the Clinical and Diagnostic Center for Movement Disorders and Botulinum Therapy of the Republic of Tatarstan from 2011 to 2014. Results and conclusions. In the group of patients we studied, tics were more common in males (in 71.6% of cases), and patients with Tourette’s syndrome were numerically predominant, taking into account the visits to the Clinical and Diagnostic Center for Movement Disorders and Botulinum Therapy of the Republic of Tatarstan. Clinical manifestations of obsessive-compulsive disorders were found not only in patients with Tourette’s syndrome, but they are characteristic of 53.2% of patients with tic hyperkinesis of various severity and phenomenology. Also, regardless of the structural and phenomenological characteristics of tic hyperkinesis, they were almost always associated with attention deficit hyperactivity disorder with a predominance of hyperactivity.

The existing treatment of somatoform dysfunction (SD), reaction to severe stress (RSS) and adjustment disorders (AjD) is insufficiently effective and safe. Anxiolytic drug Tenoten (Materia Medica Holding) is shown to be effective in clinical trials (CT). Objectives The aim of multicenter double-blind placebo-controlled randomized CT was to investigate the safety and efficacy of Tenoten in the anxiety treatment of adults with SD, RSS, AjD and other neurotic disorders (oNDs). Methods 390 adults with SD, RSS and AjD or oNDs with the Hospital Anxiety and Depression scale-anxiety (HADS-A) score≥11 were randomized into 4 groups (Tenoten group 14 tablets/day n=127; Tenoten group 3 8 tablets/day n=131, combined Placebo group 2+4 n= 132). The changes from baseline in the mean Hamilton Anxiety Rating Scale (HAM-A) score in groups 1 and 3 after 12 weeks was the primary outcome. Results The decrease in the HAM-A score from 18.81±5.81 to 7.26±4.63 (group 1) and from 18.38±4.3 to 6.40±4.02 (group 3) was observed post-treatment (p group 1/placebo =0.0055, p group 3/placebo <0.0001). The mean changes in the scores in the groups 1, 3 and the Placebo were 11.25, 11.91 and 9.71, respectively. In total, 46 AEs (28 AEs in the Tenoten groups, 18 in the Placebo) were registered in 37 patients (20 in the Tenoten groups, and 17 in the Placebo). No differences in frequency of AEs between groups were found. Conclusions Tenoten was shown to be significantly more effective than placebo in the anxiety treatment of adults with SD, RSS, AjD and oNDs (clinicaltrials.gov NCT03036293).